OKYO Pharma to Present at Eyecelerator, Engage Key Ophthalmic Conferences
Event summary
- OKYO Pharma to present at Eyecelerator on October 8, 2026, focusing on unmet needs in corneal and anterior segment diseases.
- CEO Robert J. Dempsey to lead the presentation, moderated by Julie Schallhorn, MD, MS, and Kendall Donaldson, MD.
- Company to engage with optometric and ophthalmology experts at American Academy of Optometry (Sept 30 - Oct 1) and American Academy of Ophthalmology (Oct 9-12).
- OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of 2026 for urcosimod in treating NCP.
The big picture
OKYO Pharma's participation in key ophthalmic conferences underscores its strategic focus on engaging both optometrists and ophthalmologists, critical stakeholders in the diagnosis and treatment of neuropathic corneal pain (NCP). The company's upcoming Phase 3 trial for urcosimod represents a pivotal step in validating its therapeutic approach in a competitive market. Success in these engagements could enhance OKYO's visibility and credibility among healthcare professionals, potentially accelerating its path to commercialization.
What we're watching
- Clinical Trial Progress
- The pace at which OKYO initiates its Phase 3 trial for urcosimod will signal execution capabilities and timelines for potential regulatory approval.
- Market Engagement
- How effectively OKYO leverages these conferences to build relationships with optometrists and ophthalmologists could impact future adoption of its therapies.
- Competitive Positioning
- Whether OKYO can differentiate itself in the crowded space of corneal and anterior segment disease treatments through its scientific presentations.